Company / PP&E (Net)
Taysha Gene Therapies, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$6.7M
FY2025
5-year range
$6.7M / $50.6M
FY2021-FY2025
Trend
-10.0%
vs FY2024
Sector context
#105 of 193
Health Care
What the data says
At $7M, Taysha Gene Therapies, Inc.'s pp&e (net) ranks #105 of 193 in the Health Care sector. PP&E (Net) has declined for 4 consecutive years, from $51M in FY2021 to $7M in FY2025.
Based on SEC 10-K filings.
$7M in FY2025 with a 5-year CAGR of +88.0%.
Declined from $11M to $7M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -23.4%
- 5-Year CAGR
- +88.0%
- 10-Year CAGR
- -
Sector benchmark
#105 of 193 in Health CareTop 54% of 193This company $6.7M Sector average $777.6M
▼
-99.1% below sector average
Key checks
Key Insights
- Taysha Gene Therapies, Inc.'s pp&e (net) has declined for 4 consecutive years.
- 5-year CAGR of +88.0%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 10.0% year-over-year.
- Ranks #105 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.7M | -10.0% |
| FY2024 | $7.5M | -30.9% |
| FY2023 | $10.8M | -27.6% |
| FY2022 | $15.0M | -70.4% |
| FY2021 | $50.6M | +17534.1% |
| FY2020 | $287.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026